Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by L & S Advisors Inc

L & S Advisors Inc increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 156.7% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 7,674 shares of the medical research company’s stock after purchasing an additional 4,684 shares during the quarter. L & S Advisors Inc’s holdings in Thermo Fisher Scientific were worth $4,747,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Smithfield Trust Co raised its position in shares of Thermo Fisher Scientific by 1.6% during the 3rd quarter. Smithfield Trust Co now owns 6,048 shares of the medical research company’s stock valued at $3,731,000 after buying an additional 96 shares during the period. Integrated Investment Consultants LLC raised its position in Thermo Fisher Scientific by 34.2% in the third quarter. Integrated Investment Consultants LLC now owns 1,009 shares of the medical research company’s stock valued at $624,000 after purchasing an additional 257 shares during the period. German American Bancorp Inc. raised its position in Thermo Fisher Scientific by 10.0% in the third quarter. German American Bancorp Inc. now owns 10,188 shares of the medical research company’s stock valued at $6,302,000 after purchasing an additional 927 shares during the period. Landscape Capital Management L.L.C. purchased a new stake in Thermo Fisher Scientific in the third quarter valued at approximately $235,000. Finally, Intech Investment Management LLC raised its position in Thermo Fisher Scientific by 8.8% in the third quarter. Intech Investment Management LLC now owns 3,417 shares of the medical research company’s stock valued at $2,114,000 after purchasing an additional 275 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In other news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the completion of the transaction, the senior vice president now directly owns 12,736 shares of the company’s stock, valued at approximately $7,134,197.76. The trade was a 13.57 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the transaction, the executive vice president now directly owns 16,663 shares of the company’s stock, valued at $9,333,946.08. The trade was a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 37,150 shares of company stock valued at $20,651,865 in the last quarter. Company insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of research analyst reports. Redburn Atlantic began coverage on Thermo Fisher Scientific in a research report on Monday, October 14th. They issued a “buy” rating and a $680.00 target price on the stock. Sanford C. Bernstein dropped their price target on shares of Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating for the company in a research note on Thursday, October 24th. Stifel Nicolaus dropped their price target on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. Royal Bank of Canada dropped their price target on shares of Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Finally, TD Cowen boosted their price target on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $649.33.

Thermo Fisher Scientific Stock Up 0.7 %

Shares of NYSE TMO opened at $512.86 on Thursday. Thermo Fisher Scientific Inc. has a 1 year low of $476.45 and a 1 year high of $627.88. The firm’s 50 day moving average price is $579.63 and its 200 day moving average price is $580.98. The firm has a market cap of $196.17 billion, a P/E ratio of 32.15, a price-to-earnings-growth ratio of 3.37 and a beta of 0.79. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. During the same quarter last year, the firm posted $5.69 EPS. The business’s revenue for the quarter was up .2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.67 earnings per share for the current year.

Thermo Fisher Scientific declared that its Board of Directors has approved a share buyback plan on Friday, November 15th that authorizes the company to buyback $4.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to repurchase up to 2% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.30%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.78%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.